Relmada Therapeutics Announces Closing of $115 Million Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

[In The News]

NEW YORK, Dec. 9, 2019 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced the closing of its previously announced underwritten public offering of...

View the full article